How AI and ML Are Helping Drug Discovery Teams Overcome Challenges and Offer Explainable Analytics

The AI Drug Discovery Landscape

Drug discovery is an active area for artificial intelligence (AI) and machine learning (ML) innovation, but the catchall phrase AI in drug discovery now encompasses a broad collection of technologies that look to solve fundamentally different problems. What might have begun as a relatively narrow set of predictive modeling approaches has exploded into a diverse ecosystem of specializations that span molecular design and computational chemistry, biomarker and target discovery, causal network inference, multi-omics analytics, clinical trial optimization, and agentic assessments for pipeline or asset ranking.

Global agencies continue to report growing implementation of AI and ML throughout the drug development lifecycle. At the same time, biopharma and biotech researchers work to develop AI platforms for specialized applications, including generative chemistry or physics-informed molecular design, phenomics-first systems, target- and modality-discovery platforms, and decision support, among others.

Different AI/ML Technologies Address Distinct Problems

The nuanced and data-intensive nature of the modern biopharma landscape is too complex for any single artificial intelligence architecture to tackle alone. This necessitates the application of a suite of AI models at various stages of the R&D pipeline based on the question to be addressed. These can be grouped into broad categories, including:

• Target, Pathway, and Biomarker Discovery
  Phenomics, multi-omics, knowledge graphs, and biological network analysis train, contextualize, and identify disease drivers, therapeutic targets or pathways, and biomarkers.
• Generative Chemistry, Molecular Design, and Physics-Based Modeling
  Generative AI for molecular optimization, molecular dynamics, docking, quantum chemistry, free-energy perturbation (FEP), and physics-informed modeling design and evaluate new therapeutics⁴.
• Data Infrastructure, Integration & Knowledge Platforms
  Data harmonization, multimodal integration, federated learning, knowledge graphs, interoperability, governance, traceability, and AI-ready data pipelines support downstream analytics
• Patient Stratification, Clinical Data Mining, and Clinical Trial Optimization 
  Clinical, molecular, and real-world data identify responder and non-responder populations, companion diagnostics, treatment-effect heterogeneity, and clinical outcome predictors for precision medicine. Concurrently, trial simulation, digital twins, synthetic control arms, patient recruitment, site selection, protocol optimization, and outcome prediction improve trial design and accelerate clinical development⁵.
• Evidence-based Decisioning Support, Simulation, and Neutral Judgement
  Structured comparisons, scenario modeling, tradeoff analysis, uncertainty analysis with assumption testing, evidence synthesis and integration, prioritization frameworks, and decision analytics support transparent and auditable decisions by experts or committees⁶.

Each category represents a significant bottleneck within the drug discovery and development cycle, and application of the proper AI models can reduce development time and mitigate risk.^1,2,3 Understanding these distinctions helps explain why pharmaceutical organizations often maintain multiple AI units or partnerships concurrently, to leverage these platform specializations that are complementary and application specific.

The Value of Explainable AI and Biological Context-Aware Agents

Within the context of AI- and genAI-enabled process implementation, there is a growing recognition of the importance of explainable AI. This is especially true in processes that are meant to assist experts in making complex decisions in biopharma. Though many early machine learning (ML) systems may have prioritized predictive performance early in the funnel or sprinkled throughout,  pharma R&D and clinical committees are increasingly relying on more than just accurate predictions. . Scientists, regulators, and clinical teams need to understand, justify, and explain the basis for AI-assisted decisions that may ultimately impact strategies in public health, pipeline prioritization, and resource management.

As a result, AI-assisted explainability has become increasingly important for teams that make actionable decisions in several common drug discovery and development scenarios:

• Biomarker and target decisions
• Protocol and process decisions, including technical criteria
• Patient selection, subgroup identification, clinical trial design decisions
• Asset and portfolio, as well as regulatory submission decisions

Our attention is steadily shifting from simply building powerful models toward building evidence-backed, truthful, and transparent systems whose outputs stay consistent and can be reviewed and challenged by appropriate domain experts.⁶

AI and ML Will Continue to Empower Drug Discovery Teams

Application of AI in biopharma provides the opportunity to augment human expertise by surfacing signals and networks that might otherwise remain hidden inside massive, large-scale, and fragmented biomedical data troves. The success of this approach will ultimately rest on its ability to deliver findings in a way that is scientifically interpretable, reproducible within defined iterations, and actionable.

AI applications in drug discovery have come a long way. They are not a single technology pillar, but an ecosystem of specialized approaches touching target and biomarker discovery, molecular design, data infrastructure, clinical analytics, and decision support. As these technologies mature, and other avenues for use become commonplace, teams focused on multi-omics integration, privacy-preserving data harmonization, and AI-human governance will continue to be foundational requirements to fully leverage trustworthy scientific insights and decisions.

Select References

1. Liu, Z., Roberts, R. A., Lal-Nag, M., Chen, X., Huang, R., & Tong, W. (2021). AI-based language models powering drug discovery and development. Drug discovery today, 26(11), 2593–2607. doi.org/10.1016/j.drudis.2021.06.009
2. Gorostiola González, M., Janssen, A. P. A., IJzerman, A. P., Heitman, L. H., & van Westen, G. J. P. (2022). Oncological drug discovery: AI meets structure-based computational research. Drug discovery today, 27(6), 1661–1670. doi.org/10.1016/j.drudis.2022.03.005
3. Zhang, Y., Liu, C., Liu, M., Liu, T., Lin, H., Huang, C. B., & Ning, L. (2023). Attention is all you need: utilizing attention in AI-enabled drug discovery. Briefings in bioinformatics, 25(1), bbad467. doi.org/10.1093/bib/bbad467
4. Jiménez-Luna, J., Grisoni, F., Weskamp, N., & Schneider, G. (2021). Artificial intelligence in drug discovery: recent advances and future perspectives. Expert opinion on drug discovery, 16(9), 949–959. doi.org/10.1080/17460441.2021.1909567
5. Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P. (2024). Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert opinion on drug discovery, 19(1), 33–42. doi.org/10.1080/17460441.2023.2273839
6. Labkoff, S., Oladimeji, B., Kannry, J., Solomonides, A., Leftwich, R., Koski, E., Joseph, A. L., Lopez-Gonzalez, M., Fleisher, L. A., Nolen, K., Dutta, S., Levy, D. R., Price, A., Barr, P. J., Hron, J. D., Lin, B., Srivastava, G., Pastor, N., Luque, U. S., Bui, T. T. T., … Quintana, Y. (2024). Toward a responsible future: recommendations for AI-enabled clinical decision support. Journal of the American Medical Informatics Association : JAMIA, 31(11), 2730–2739. doi.org/10.1093/jamia/ocae209